Author's response to reviews

**Title:** Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies

**Authors:**

Jin Li (fudanlijin@163.com)
Xinmin Zhao (mizuyi@hotmail.com)
Lei Chen (chenlei350401@sohu.com)
Haiyi Guo (guohaiyi-sh@hotmail.com)
Fangfang Lv (lvff80@yahoo.com)
Ka Jia (fudanjiaka@163.com)
Ke Yv (yuk@mail.shcnc.ac.cn)
Fengqing Wang (wfg@mail.shcnc.ac.cn)
Chuan Li (chli@mail.shcnc.ac.cn)
Jun Qian (junqian68@hotmail.com)

**Version:** 4  **Date:** 14 September 2010

**Author's response to reviews:** see over
Dear Editor,

Revised manuscript (# - 4133455573803329)

Thank you very much for your acceptance of our manuscript titled Safety and Pharmacokinetics of Novel Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor YN968D1 in Patients with Advanced Malignancies.

We thank you to reviewers for their further work and comments. Change "(HFS)" has been added to the phrases as recommended.

2006 AACR presentation/poster on apatinib will be sent to you by your E-mail address as requested by one of the reviewers, Prof. Peter Fong. Your assistance is greatly appreciated.

Thank you again for your time.

Yours sincerely,

Jin Li